ArticleBioinformation2026
Role of CBNAAT and ADA in tubercular pleural effusion diagnosis at BMGMC hospital.
Article in Bioinformation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In 2024, 10.8 million new tuberculosis cases were reported globally. Of these, 19% were extrapulmonary (EPTB), meaning the infection occurred outside the lungs. Tuberculous pleural effusion (TPE) is a difficult disease to diagnose because it is only paucibacillary, so consideration should be given to the rapid and easily available diagnostic tools in high tuberculosis prevalence environments. The study was an observational study aimed at assessing diagnostic value of adenosine deaminase (ADA) and Cartridge-Based Nucleic Acid Amplification Test (CBNAAT) in 200 patients with pleural effusion in a tertiary care center. This study established high sensitivity (92.5) but poor specificity (50) of ADA at 40 IU/L cut off; and low sensitivity (28.35) but high specificity (50) of CBNAAT at 40 IU/L cut off. Effusions of tuberculosis were 67 percent with males being the most at 68 percent in the age group of 41 to 50. There was a strong positive correlation between the lymphocyte predominance with the ADA levels (r=0.71, P=0.003) and the CBNAAT positivity (r=0.95, P=0.0015). Thus, we show that ADA is still a useful screening method in tuberculous pleural effusion, especially when it is used in conjunction with lymphocyte-predominant exudates and CBNAAT is a confirmatory study with the further benefit of identifying rifampicin resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.